Bridgebio Pharma, Inc. · NASDAQ:BBIO

Kumar Neil sold 51,563 Bridgebio Pharma, Inc. shares (Form 4)

Traded Jun 4 to Jun 5, 2026 · Filed Jun 8, 2026

From Jun 4 to Jun 5, 2026, Kumar Neil (Director, Chief Executive Officer) sold 51,563 Bridgebio Pharma, Inc. shares at an average US$67.71 for US$3.49M under a trading plan, leaving 4,318,447 shares. Filed Jun 8, 2026 (Form 4).

Sold
51,563 shares
Price
US$67.71 average (US$65.72 to US$68.96)
Value
US$3.49M
Holding after
4,318,447 shares (held indirectly)
Trading plan
Yes (Made under a plan set in advance)
Role
Director, Chief Executive Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Jun 4, 2026Common StockSale2,200US$65.72553,486Indirect
Jun 4, 2026Common StockSale1,429US$66.72552,057Indirect
Jun 4, 2026Common StockSale15,921US$67.74536,136Indirect
Jun 4, 2026Common StockSale450US$68.27535,686Indirect
Jun 5, 2026Common StockSale7,147US$67.20528,539Indirect
Jun 5, 2026Common StockSale8,437US$67.88520,102Indirect
Jun 5, 2026Common StockSale4,416US$68.96515,686Indirect
Jun 5, 2026Common StockSale7,148US$67.204,331,299Indirect
Jun 5, 2026Common StockSale4,415US$68.964,318,447Indirect

Source

View original at SEC

Related